<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31450699</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>17</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20174152</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder affecting upper and lower motor neurons (MNs) that still lacks an efficacious therapy. The failure of recent therapeutic trials in ALS, other than depending on the poor knowledge of pathogenic mechanisms responsible for MNs loss, is largely due to diagnostic delay and the lack of reliable biomarkers for diagnosis, prognosis and response to pharmacologic intervention. Neurofilaments (Nfs) are neuron-specific cytoskeletal proteins, whose levels increased in biological fluids proportionally to the degree of axonal damage, both in normal and in pathologic conditions, representing potential biomarkers in various neurological disorders, such as motor neuron disorder (MND). Growing evidence has shown that phosphorylated neurofilaments heavy chain (p-NfH) and neurofilaments light chain (NfL) are increased in blood and cerebrospinal fluid (CSF) of ALS patients compared to healthy and neurological controls and are found to correlate with disease progression. In this review, we reported the most relevant studies investigating the diagnostic and prognostic role of Nfs in ALS. Given their reliability and reproducibility, we consider Nfs as promising and useful biomarkers in diagnosis of MND, early patient identification for inclusion in clinical trials, prediction of disease progression, and response to pharmacological intervention, and we suggest the validation of their measurement in clinical activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gagliardi</LastName><ForeName>Delia</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8460-938X</Identifier><AffiliationInfo><Affiliation>Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneri</LastName><ForeName>Megi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saccomanno</LastName><ForeName>Domenica</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bresolin</LastName><ForeName>Nereo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comi</LastName><ForeName>Giacomo Pietro</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurmuscular and Rare Diseases Unit, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, 20122 Milan, Italy. stefania.corti@unimi.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy. stefania.corti@unimi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">blood</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">neurofilaments</Keyword><Keyword MajorTopicYN="N">p-NfH</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31450699</ArticleId><ArticleId IdType="pmc">PMC6747516</ArticleId><ArticleId IdType="doi">10.3390/ijms20174152</ArticleId><ArticleId IdType="pii">ijms20174152</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee M.K., Cleveland D.W. Neuronal Intermediate Filaments. Annu. Rev. Neurosci. 1996;19:187&#x2013;217. doi: 10.1146/annurev.ne.19.030196.001155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.ne.19.030196.001155</ArticleId><ArticleId IdType="pubmed">8833441</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Teunissen C.E., Otto M., Piehl F., Sormani M.P., Gattringer T., Barro C., Kappos L., Comabella M., Fazekas F., et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018;14:577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann H., Aebi U. Intermediate Filaments: Structure and Assembly. Cold Spring Harb. Perspect. Biol. 2016;8 doi: 10.1101/cshperspect.a018242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a018242</ArticleId><ArticleId IdType="pmc">PMC5088526</ArticleId><ArticleId IdType="pubmed">27803112</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H. Flow rate of cerebrospinal fluid (CSF)&#x2014;A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994;122:189&#x2013;203. doi: 10.1016/0022-510X(94)90298-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90298-4</ArticleId><ArticleId IdType="pubmed">8021703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J., Norgren N., Dobson R., Topping J., Nissim A., Malaspina A., Bestwick J.P., Monsch A.U., Regeniter A., Lindberg R.L., et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE. 2013;8:e75091. doi: 10.1371/journal.pone.0075091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075091</ArticleId><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkels&#xf8; C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 1996;67:2013&#x2013;2018. doi: 10.1046/j.1471-4159.1996.67052013.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67052013.x</ArticleId><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Ren Y., Zhu W., Yang F., Zhang X., Huang X. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J. Neurol. Sci. 2016;367:269&#x2013;274. doi: 10.1016/j.jns.2016.05.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.05.062</ArticleId><ArticleId IdType="pubmed">27423602</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M., Jeromin A., Gille B., Claeys K.G., Herbst V., Brix B., Van Damme P., Poesen K. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2018;89:367&#x2013;373. doi: 10.1136/jnnp-2017-316605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E., Bedin R., Fasano A., Fini N., Gessani A., Vinceti M., Mandrioli J. Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study. Neurodegener. Dis. 2018;18:255&#x2013;261. doi: 10.1159/000493986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000493986</ArticleId><ArticleId IdType="pubmed">30428468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N., Giovannoni G., Fratta P., Sidle K., Fish M., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke R.A.L., Gray E., Lu C.H., Kuhle J., Talbot K., Malaspina A., Turner M.R. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann. Clin. Transl. Neurol. 2015;2:748&#x2013;755. doi: 10.1002/acn3.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P., Oeckl P., Huss A., M&#xfc;ller K., Volk A.E., Kuhle J., Knehr A., Andersen P.M., Prudlo J., Steinacker P., et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 2016;79:152&#x2013;158. doi: 10.1002/ana.24552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Henderson R.D., David M., McCombe P.A. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11:e0164625. doi: 10.1371/journal.pone.0164625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Petzold A., Topping J., Allen K., Macdonald-Wallis C., Clarke J., Pearce N., Kuhle J., Giovannoni G., Fratta P., et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: Insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry. 2015;86:565&#x2013;573. doi: 10.1136/jnnp-2014-307672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K.B., Glass J.D., Crook J.E., Yang C., Thomas C.S., Desaro P., Johnston A., Overstreet K., Kelly C., Polak M., et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:467&#x2013;472. doi: 10.1136/jnnp-2012-303768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P., Pfluger C., Singh P., Lim C., Airey C., Henderson R. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J. Neurol. Sci. 2015;353:122&#x2013;129. doi: 10.1016/j.jns.2015.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.032</ArticleId><ArticleId IdType="pubmed">25958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K., De Schaepdryver M., Stubendorff B., Gille B., Muckova P., Wendler S., Prell T., Ringer T.M., Rhode H., Stevens O., et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302&#x2013;2309. doi: 10.1212/WNL.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Heckman M.G., Diehl N.N., Wuu J., Miller T.M., Pastor P., Trojanowski J.Q., Grossman M., Berry J.D., Hu W.T., et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Feneberg E., Weishaupt J., Brettschneider J., Tumani H., Andersen P.M., von Arnim C.A., B&#xf6;hm S., Kassubek J., Kubisch C., et al. Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:12&#x2013;20. doi: 10.1136/jnnp-2015-311387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E., Oeckl P., Steinacker P., Verde F., Barro C., Van Damme P., Gray E., Grosskreutz J., Jardel C., Kuhle J., et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22&#x2013;e30. doi: 10.1212/WNL.0000000000004761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L., Blennow K., Calabresi P., Di Filippo M., Parnetti L., Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 2019;90:870&#x2013;881. doi: 10.1136/jnnp-2018-320106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Ruggieri M., Cortese R., D&#x2019;Errico E., Capozzo R., Leo A., Mastrapasqua M., Zoccolella S., Leante R., Livrea P., et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: A possible marker of disease severity and progression. Eur. J. Neurol. 2012;19:1561&#x2013;1567. doi: 10.1111/j.1468-1331.2012.03777.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03777.x</ArticleId><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Steinacker P., Weishaupt J.H., Kassubek J., Oeckl P., Halbgebauer S., Tumani H., von Arnim C.A.F., Dorst J., Feneberg E., et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A., Martinelli I., Bello L., Querin G., Puthenparampil M., Ruggero S., Toffanin E., Cagnin A., Briani C., Pegoraro E., et al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017;74:525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Goossens J., Dedeene L., De Vocht J., Oldoni E., Goris A., Van Den Bosch L., Depreitere B., Claeys K.G., et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol. Appl. Neurobiol. 2019;45:291&#x2013;304. doi: 10.1111/nan.12511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D., Volanti P., Brambilla L., Colletti T., Spataro R., La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 2018;265:510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>